|
|
||||||
 |
||||||
|
part 1: CNV and Anti-VEGF Therapy Updated: 2010-05-21 22:58:07 Description: Subject: part 1: CNV and Anti-VEGF Therapy Paper Discussed: Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology, June 2005, 112(6) p1035-47 Guest: Philip J. Rosenfeld, M.D., Ph.D. Associate Professor of Ophthalmology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida LISTEN NOW | DOWNLOAD |
|
|||||
